Study results in a rare form of obesity could help the company expand use of Imcivree, which is approved for two genetically driven forms of excess weight.

Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...

Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...

Mounjaro and Zepbound are Eli Lilly's ... 42.5 billion yen -- down from the initial forecast of 56.5 billion yen. The company cited delays in the sales launch in the U.S. for the newly protracted ...

BofA on Friday forecast first-quarter sales to come in 1% to 2% below current market consensus ... closely-watched weekly U.S. prescription data for Novo's Wegovy and Lilly's Zepbound. Barclays in a ...

Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an ...

Lilly made $1.26 billion from Zepbound sales in the third quarter, around $500 million lower than analyst forecasts, before the comparative data with Wegovy was reported. GlobalData recently ...

BofA on Friday forecast first-quarter sales to come in 1% to 2% below current ... U.S. prescription data for Novo’s Wegovy and Lilly’s Zepbound. Barclays in a note on Friday said prescriptions ...